Distinct regulation of plasma LDL cholesterol by eicosapentaenoic acid and docosahexaenoic acid in high fat diet-fed hamsters: Participation of cholesterol ester transfer protein and LDL receptor

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 88, Issue 4, 2013, Pages 281-288

  Ishida, Takayuki ^a   Ohta, Masahiko ^a   Nakakuki, Masanori ^a   Kami, Hideaki ^a   Uchiyama, Ryota ^a   Kawano, Hiroyuki ^a   Notsu, Tatsuto ^a   Imada, Kazunori ^a   Shimano, Hitoshi ^b  

^a MOCHIDA PHARMACEUTICAL CO   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Cholesteryl ester transfer protein; Docosahexaenoic acid; Eicosapentaenoic acid; Low density lipoprotein; N 3 polyunsaturated fatty acids

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; DOCOSAHEXAENOIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; OMEGA 3 FATTY ACID; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEPG2; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; FOOD INTAKE; GENE EXPRESSION; HAMSTER; HUMAN; HUMAN CELL; LIPID COMPOSITION; LIPID DIET; MALE; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SREBP1 GENE; SREBP2 GENE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WHITE ADIPOSE TISSUE;

ANIMALS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, LDL; CRICETINAE; DIET, HIGH-FAT; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; RECEPTORS, LDL;

ANIMALIA; CRICETINAE;

EID: 84880046142     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2013.01.001     Document Type: Article

References (31)

1. Breslow J.L. n-3 fatty acids and cardiovascular disease. Am. J. Clin. Nutr. 2006, 83:1477S-1482S.
2. Dimitrow P.P., Jawien M. Pleiotropic, cardioprotective effects of omega-3 polyunsaturated fatty acids. Mini. Rev. Med. Chem. 2009, 9:1030-1039.
3. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
4. Westphal S., Orth M., Ambrosch A., Osmundsen K., Luley C. Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n-3 fatty acids. Am. J. Clin. Nutr. 2000, 71:914-920.
5. Calabresi L., Villa B., Canavesi M., et al. An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism 2004, 53:153-158.
6. Calabresi L., Donati D., Pazzucconi F., Sirtori C.R., Franceschini G. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis 2000, 148:387-396.
7. Jacobson T.A. Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Am. J. Clin. Nutr. 2008, 87:1981S-1990S.
8. Wei M.Y., Jacobson T.A. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr. Atheroscler. Rep. 2011, 13:474-483.
9. Mori T.A., Burke V., Puddey I.B., et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am. J. Clin. Nutr. 2000, 71:1085-1094.
10. Grimsgaard S., Bonaa K.H., Hansen J.B., Nordøy A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am. J. Clin. Nutr. 1997, 66:649-659.
11. Woodman R.J., Mori T.A., Burke V., Puddey I.B., Watts G.F., Beilin L.J. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am. J. Clin. Nutr. 2002, 76:1007-1015.
12. Singh V., Tiwari R.L., Dikshit M., Barthwal M.K. Models to study atherosclerosis: a mechanistic insight. Curr. Vasc. Pharmacol. 2009, 7:75-109.
13. Okazaki M., Usui S., Ishigami M., et al. Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler. Thromb. Vasc. Biol. 2005, 25:578-584.
14. Mizuguchi K., Yano T., Ishibashi M., Masada A., Mizota M., Saito Y. Ethyl all-cis-5,8,11,14,17-icosapentaenoate modifies the biochemical properties of rat very low-density lipoprotein. Eur. J. Pharmacol. 1993, 235:221-227.
15. Sato A., Kawano H., Notsu T., et al. Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity: importance of hepatic lipogenesis. Diabetes 2010, 59:2495-2504.
16. Leigh-Firbank E.C., Minihane A.M., Leake D.S., et al. Eicosapentaenoic acid and docosahexaenoic acid from fish oils: differential associations with lipid responses. Br. J. Nutr. 2002, 87:435-445.
17. Mori T.A., Watts G.F., Burke V., Hilme E., Puddey I.B., Beilin L.J. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 2000, 102:1264-1269.
18. Geppert J., Kraft V., Demmelmair H., Koletzko B. Microalgal docosahexaenoic acid decreases plasma triacylglycerol in normolipidaemic vegetarians: a randomized trial. Br. J. Nutr. 2006, 95:779-786.
19. Nissen S.E., Tardif J.C., Nicholls S.J., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 2007, 356:1304-1316.
20. Spady D.K., Horton J.D., Cuthbert J.A. Regulatory effects of n-3 polyunsaturated fatty acids on hepatic LDL uptake in the hamster and rat. J. Lipid. Res. 1995, 36:1009-1020.
21. Schectman G., Boerboom L.E., Hannah J., Howard B.V., Mueller R.A., Kissebah A.H. Dietary fish oil decreases low-density-lipoprotein clearance in nonhuman primates. Am. J. Clin. Nutr. 1996, 64:215-221.
22. Zampolli A., Bysted A., Leth T., Mortensen A., De Caterina R., Falk E. Contrasting effect of fish oil supplementation on the development of atherosclerosis in murine models. Atherosclerosis 2006, 184:78-85.
23. Radeau T., Robb M., Lau P., Borthwick J., McPherson R. Relationship of adipose tissue cholesteryl ester transfer protein (CETP) mRNA to plasma concentrations of CETP in man. Atherosclerosis 1998, 139:369-376.
24. Jiang X.C., Moulin P., Quinet E., et al. Mammalian adipose tissue and muscle are major sources of lipid transfer protein mRNA. J. Biol. Chem. 1991, 266:4631-4639.
25. Surette M.E., Whelan J., Lu G.P., Broughton K.S., Kinsella J.E. Dependence on dietary cholesterol for n-3 polyunsaturated fatty acid-induced changes in plasma cholesterol in the Syrian hamster. J. Lipid Res. 1992, 33:263-271.
26. Berr F., Goetz A., Schreiber E., Paumgartner G. Effect of dietary n-3 versus n-6 polyunsaturated fatty acids on hepatic excretion of cholesterol in the hamster. J. Lipid Res. 1993, 34:1275-1284.
27. Amemiya-Kudo M., Shimano H., Hasty A.H., et al. Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes. J. Lipid Res. 2002, 43:1220-1235.
28. Yahagi N., Shimano H., Hasty A.H., et al. A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids. J. Biol. Chem. 1999, 274:35840-35844.
29. Pal S., Thomson A.M., Bottema C.D., Roach P.D. Polyunsaturated fatty acids downregulate the low density lipoprotein receptor of human HepG2 cells. J. Nutr. Biochem. 2002, 13:55-63.
30. Olano-Martin E., Anil E., Caslake M.J., et al. Contribution of apolipoprotein E genotype and docosahexaenoic acid to the LDL-cholesterol response to fish oil. Atherosclerosis 2010, 209:104-110.
31. Avramoglu R.K., Cianflone K., Sniderman A.D. Role of the neutral lipid accessible pool in the regulation of secretion of apoB-100 lipoprotein particles by HepG2 cells. J. Lipid Res. 1995, 36:2513-2528.